Multiple Myeloma Clinical Trials

A listing of Multiple Myeloma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 463 clinical trials
Integrin 7 BCMA CS1 CD38 and CD138 as the Single or Compound Targets for the Fourth Genenation of CAR-T Cells

According to the high expression of tumor cell-associated antigen CD138, integrin 7, CS1, CD38 and BCMA in patients with refractory/recurrent multiple myeloma, the fourth generation of CAR-T

  • 0 views
  • 26 Jan, 2021
  • 3 locations
Dose Exploration Study OF JWCAR129 BCMA-Targeted CART for RRMM

maturation antigen (BCMA), in adult subjects with relapsed and/or refractory multiple myeloma.

  • 0 views
  • 27 Jan, 2021
  • 1 location
Muscle Stimulation for Physical Function During Stem Cell Transplant

Some blood, bone marrow, and lymphatic (hematologic) cancers such as Hodgkin/Non-Hodgkin lymphomas, chronic lymphocytic leukemia, and multiple myeloma, are over-represented in Veterans due to

  • 0 views
  • 31 May, 2021
  • 1 location
Thalidomide and Tegafur/Uracil(UFUR) in the Treatment of Advanced Colorectal Cancer

. Thalidomide is an agent, which has shown potential in the treatment of hematological and solid tissue malignancies such as multiple myeloma via antiangiogenic mechanism. Tegafur/uracil (UFUR) is one

measurable disease
irinotecan
antineoplastic
liver metastasis
metastasis
  • 7 views
  • 07 Nov, 2020
  • 1 location
Selinexor and Backbone Treatments of Multiple Myeloma Patients

relapsed/refractory multiple myeloma (RRMM) and newly diagnosed multiple myeloma (NDMM). The combinations to be evaluated are: Arm 1: Selinexor + dexamethasone + pomalidomide (SPd)

measurable disease
immunomodulatory imide drug
elotuzumab
electrophoresis
monoclonal antibodies
  • 50 views
  • 07 May, 2021
  • 24 locations
A Study of WVT078 in Patients With Multiple Myeloma (MM)

relapses and/or refractory Multiple Myeloma (MM)

proteasome inhibitor
immunomodulatory imide drug
refractory multiple myeloma
  • 8 views
  • 12 Jun, 2021
  • 12 locations
An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma

ASCT during initial treatment (Cohort 2c) Approximately 181 subjects will be enrolled into one of two cohorts. Cohort 1 will enroll approximately 73 RRMM subjects with 3 prior anti-myeloma treatment

measurable disease
cell transplantation
induction therapy
dexamethasone
electrophoresis
  • 12 views
  • 26 Jan, 2021
  • 25 locations
Allograft for Sickle Cell Disease and Thalassemia

survival, graft versus myeloma effect) and to evaluate its toxicity profile (immediate toxicity, graft-versus-host disease, graft rejection, mortality) in a patient population with severe congenital

  • 28 views
  • 18 Feb, 2021
  • 1 location
Study of Melphalan Flufenamide (Melflufen) in Combination With Daratumumab in Relapsed Refractory Multiple Myeloma

This is a randomized, controlled, open-label, Phase 3 multicenter study which will enroll patients that have Relapsed Refractory Multiple Myeloma and are double refractory to an Immunomodulatory

dexamethasone
refractory multiple myeloma
progressive disease
melphalan
  • 0 views
  • 02 Jun, 2021
  • 32 locations
Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma

and dexamethasone (Arm B) in participants with relapsed/refractory multiple myeloma (RRMM).

measurable disease
cancer
lenalidomide
dexamethasone
refractory multiple myeloma
  • 0 views
  • 10 Jun, 2021
  • 37 locations